Jubilant Pharmova Limited

As of June 30, 2026, Jubilant Pharmova Limited carries a market capitalization of 153.78B, placing it among publicly traded companies globally. Its enterprise value stands at 153.78B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Jubilant Pharmova Limited's next confirmed earnings release is scheduled for October 30, 2026.

As of June 30, 2026, Jubilant Pharmova Limited has 158.39M shares outstanding.

As of June 30, 2026, Jubilant Pharmova Limited trades at a trailing price-to-earnings ratio of 45.96.

As of June 30, 2026, Jubilant Pharmova Limited trades at an EV/EBITDA multiple of 13.82 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.81 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 23.65 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 153.78B versus a market cap of 153.78B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 13.61M in revenue per employee across its workforce of 6,237.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Jubilant Pharmova Limited recorded 1.76B in income tax expense. That works out to an effective tax rate of 34.54, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 5.10B, leaving 3.35B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Jubilant Pharmova Limited's stock has declined approximately 16.75% over the past 52 weeks. The 50-day moving average sits at 955.69, while the 200-day moving average is 948.45.

Over the twelve months ended June 30, 2026, Jubilant Pharmova Limited generated 84.88B in revenue and converted that into 3.35B in net income, yielding earnings per share of 21.03. EBITDA reached 11.13B, while operating income came in at 7.04B.

Over the twelve months ended June 30, 2026, Jubilant Pharmova Limited posted a gross margin of 67.05, reflecting its pricing power and cost economics. The operating margin of 8.29 and net profit margin of 3.94 provide insight into operational efficiency.

Jubilant Pharmova Limited's most recent stock split took place on March 17, 2006 with a 1:5 split ratio.